{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:09:51Z","timestamp":1790014191101,"version":"4.0.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kavanagh Family Foundation and Kevin T. Doner Memorial Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small bowel adenocarcinoma (SBA) is molecularly distinct from colorectal and gastric cancers, yet treatment typically parallels colorectal cancer. We evaluated the activity of taxane-based therapy in the largest SBA cohort to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed SBA patients treated with taxane-based chemotherapy at MD Anderson Cancer Center from 1994 to 2024. Eligible patients had pathologic confirmation, received &amp;gt;1 treatment cycle, and had tumor response evaluation. Survival analyses were analyzed using Kaplan\u2013Meier and Cox proportional hazard models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy patients were identified. Median age was 57, and 59% were male. Primary sites were duodenum (44%), jejunum (34%), and ileum (16%). Metastatic sites included peritoneum (39%) and liver (31%). Common mutations were TP53 (63%), KRAS (47%), SMAD4 (24%), and APC (15%). Taxanes were administered as single agents (29%) or in combination (71%), most often in second- (40%) or third-line (33%) settings. Overall response rate was 24%. Median time to progression (mTTP) was 3.1\u2009months (95% CI: 2.0-4.2) and median overall survival (mOS) was 8.7\u2009months (95% CI: 7.4-10.1). Efficacy did not differ by treatment line, regimen type, or tumor site, but was significantly associated with TP53 status; response rate was 20% in TP53-mutated vs 45% in wild-type (P\u2009=\u2009.009), with mTTP 2.5 vs 4.9\u2009months (P\u2009=\u2009.009) and mOS 7.3 vs 10.6\u2009months (P\u2009=\u2009.002). On multivariable analysis, TP53 mutation predicted worse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taxane-based therapy demonstrated activity in metastatic SBA, with 24% response and 3.1-month mTTP. TP53 mutation may be a negative predictive marker for taxane efficacy. These findings support prospective investigation in metastatic SBA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag104","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:46:54Z","timestamp":1773924414000},"source":"Crossref","is-referenced-by-count":1,"title":["A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6102-0887","authenticated-orcid":false,"given":"Mir","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Grandhi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preksha","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Serpas","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Morelli","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Comprehensive Cancer Center , Rochester, NY 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Kalyan","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, IL 60611,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Salem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Levine Cancer Institute, Atrium Health , Charlotte, NC 28204,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Huey","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center , Charlotte, NC 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Vinocha","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-4940","authenticated-orcid":false,"given":"Jane","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-1610","authenticated-orcid":false,"given":"Robert","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026042618470831000_oyag104-B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","article-title":"Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment","volume":"46","author":"Aparicio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2026042618470831000_oyag104-B2"},{"key":"2026042618470831000_oyag104-B3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4251\/wjgo.v14.i2.413","article-title":"Small bowel adenocarcinoma: an overview","volume":"14","author":"Khosla","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"2026042618470831000_oyag104-B4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/s-0038-1660482","article-title":"Small bowel adenocarcinoma","volume":"31","author":"Chen","year":"2018","journal-title":"Clin Colon Rectal Surg"},{"key":"2026042618470831000_oyag104-B5","doi-asserted-by":"publisher","first-page":"e230631","DOI":"10.1001\/jamanetworkopen.2023.0631","article-title":"Evaluation of systemic treatments of small intestinal adenocarcinomas: a systematic review and meta-analysis","volume":"6","author":"de Back","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026042618470831000_oyag104-B6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2026042618470831000_oyag104-B7","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026042618470831000_oyag104-B8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026042618470831000_oyag104-B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/annonc\/mdx688","article-title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","volume":"29","author":"Overman","year":"2018","journal-title":"Ann Oncol"},{"key":"2026042618470831000_oyag104-B10","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1634\/theoncologist.2018-0573","article-title":"Retrospective analysis of taxane-based therapy in small bowel adenocarcinoma","volume":"24","author":"Aldrich","year":"2019","journal-title":"Oncologist"},{"key":"2026042618470831000_oyag104-B11","author":"National Comprehensive Cancer Network (NCCN)","year":"2025"},{"key":"2026042618470831000_oyag104-B12","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/cncr.25614","article-title":"Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy","volume":"117","author":"Zaanan","year":"2011","journal-title":"Cancer"},{"key":"2026042618470831000_oyag104-B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026042618470831000_oyag104-B14","doi-asserted-by":"publisher","first-page":"100132","DOI":"10.1016\/j.esmoop.2021.100132","article-title":"Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy","volume":"6","author":"Bhamidipati","year":"2021","journal-title":"ESMO Open"},{"key":"2026042618470831000_oyag104-B15","doi-asserted-by":"publisher","first-page":"e0241454","DOI":"10.1371\/journal.pone.0241454","article-title":"Genomic analysis for the prediction of prognosis in small-bowel cancer","volume":"16","author":"Tsuboi","year":"2021","journal-title":"PLoS One"},{"key":"2026042618470831000_oyag104-B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41416-024-02687-7","article-title":"Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases","volume":"131","author":"Aparicio","year":"2024","journal-title":"Br J Cancer"},{"key":"2026042618470831000_oyag104-B17","doi-asserted-by":"publisher","first-page":"20863","DOI":"10.18632\/oncotarget.4576","article-title":"Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility","volume":"6","author":"Alvi","year":"2015","journal-title":"Oncotarget"},{"key":"2026042618470831000_oyag104-B18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1470-2045(11)70094-8","article-title":"TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994\/BIG 1-00): a randomised phase 3 trial","volume":"12","author":"Bonnefoi","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026042618470831000_oyag104-B19","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/bcr3179","article-title":"Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline\/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial","volume":"14","author":"Fern\u00e1ndez-Cuesta","year":"2012","journal-title":"Breast Cancer Res BCR"},{"key":"2026042618470831000_oyag104-B20","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1200\/JCO.2000.18.23.3936","article-title":"p53 gene status and response to platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma","volume":"18","author":"Lavarino","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026042618470831000_oyag104-B21","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41401-021-00847-6","article-title":"Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells","volume":"43","author":"Shu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"2026042618470831000_oyag104-B22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/1097-0142(20000815)89:4<769::AID-CNCR8>3.0.CO;2-6","article-title":"p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma","volume":"89","author":"King","year":"2000","journal-title":"Cancer"},{"key":"2026042618470831000_oyag104-B23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/sj.onc.1201658","article-title":"The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells","volume":"16","author":"Zhang","year":"1998","journal-title":"Oncogene"},{"key":"2026042618470831000_oyag104-B24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2015.04.039","article-title":"TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas","volume":"138","author":"Seagle","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2026042618470831000_oyag104-B25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2","article-title":"A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes","volume":"92","author":"Cassinelli","year":"2001","journal-title":"Int J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag104\/67485356\/oyag104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag104\/68103132\/oyag104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag104\/68103132\/oyag104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:16Z","timestamp":1777243636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag104\/8537919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag104","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,23]]},"article-number":"oyag104"}}